AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04929509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium fluoride varnish
Description: 5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
Study NCT00986869 — intervention group
Intervention type: PROCEDURE
Intervention: Doppler echocardiogram
Description: All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
Study NCT02681835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Intubation performed using laryngoscope with Macintosh blade
Study NCT02532712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size
Study NCT01466387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi Polysaccharide Vaccine
Description: One dose of typhoid Vi polysaccharide vaccine.
Study NCT00861874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 IV, Days 1-5
Study NCT00861874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
Study NCT01947491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray
Study NCT01947491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp01 Lotion
Study NCT01466387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever Vaccine
Description: One dose of yellow fever vaccine.
Study NCT01466387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Vaccine
Description: Two doses of Japanese Encephalitis Vaccine.
Study NCT01466387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: Three doses of Rabies vaccine.
Study NCT01466387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM Vaccine
Description: One dose of MenACWY-CRM vaccine.
Study NCT02749812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant Continuous Positive Airway Pressure
Study NCT02749812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic continuous Positive Airway Pressure
Study NCT02225756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Oral administration for a short time of cyclosporine A dose 1
Study NCT02225756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Oral administration for a short time of cyclosporine A dose 2
Study NCT02225756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration for a short time of placebo
Study NCT03552614 — intervention group
Intervention type: DEVICE
Intervention: Upper limb robot-assisted rehabilitation
Description: Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames.
Study NCT03552614 — intervention group
Intervention type: OTHER
Intervention: physiotherapy
Description: Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
Study NCT00996385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib) plus Eloxatin (oxaliplatin)
Description: One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
Study NCT03943004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-14927
Description: DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
Study NCT04197999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1359
Description: Injection 10 mg/mL
Study NCT03735186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 60 min treadmill exercise performed at 60% of maximum oxygen uptake.
Study NCT02412826 — intervention group
Intervention type: DEVICE
Intervention: Abstats sensor
Description: The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
Study NCT03445780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Description: Skin cooling with ethyl chloride spray 5 seconds prior to injection
Study NCT03445780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinching
Description: Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
Study NCT03445780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Site of Procedure
Description: Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
Study NCT04166136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transition from the Rearfoot to the Forefoot and Midfoot
Description: Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
Study NCT04166136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment Group
Description: This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
Study NCT04166136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Strengthening Group
Description: The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
Study NCT00193856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Acetate
Description: LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
Study NCT00193856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate
Description: LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
Study NCT00193856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
Study NCT00193856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
Study NCT00193856 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional external beam therapy
Description: The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
Study NCT03512873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Subjects will be treated with tranilast
Study NCT03717012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: stable dose
Study NCT03717012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: stable dose
Study NCT03717012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Description: 12 weeks
Study NCT03838900 — intervention group
Intervention type: DEVICE
Intervention: Loop
Description: The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
Study NCT03254264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model
Description: ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery.
Study NCT03254264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'as-usual' intervention
Description: a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
Study NCT02671929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-help program
Description: Access to the internet-based self-help program
Study NCT02671929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-help program
Description: Access to the internet-based self-help program
Study NCT00193856 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional external beam therapy
Description: The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
Study NCT04013633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifesaver virtual reality training
Description: CPR training using the Lifesaver virtual reality application
Study NCT04013633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face training
Description: Short face-to-face CPR training
Study NCT04763187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: Tooth extraction and alveolus regeneration with autologous blood concentrate.
Study NCT04763187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth extraction and alveolus regeneration with autologous blood concentrate.
Study NCT02940782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc single file system
Description: A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
Study NCT02940782 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Shape single file system
Description: A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
Study NCT02940782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland
Description: It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
Study NCT02940782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland
Description: It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
Study NCT01947491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Study NCT01947491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Study NCT00724009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
Study NCT03609476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature saline instillation
Description: Saline is used as room temperature
Study NCT03609476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warmed saline instillation
Description: Saline is warmed to 37Celcius prior to instillation
Study NCT03609476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No saline instillation
Description: No saline is used prior to catheter removal
Study NCT04187482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
Study NCT00667654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Description: Testing a range of dosing configurations to optimize patient tolerability
Study NCT03013556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A, TDF
Description: TDF for 96 weeks
Study NCT03013556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B:TDF then TDF and Peginterferon alfa-2a
Description: Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
Study NCT03013556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group C:TDF and Peginterferon alfa-2a then TDF
Description: Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
Study NCT03374202 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VRC-HIVAAV070-00-GT (AAV8-VRC07)
Description: AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
Study NCT04386499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
Study NCT04386499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: 400 mcg of folic acid
Study NCT01635764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study NCT04063787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fist Assist
Description: The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12.
Study NCT02124954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Study NCT02124954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02124954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT02266875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline
Study NCT02266875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard saline
Study NCT00204867 — intervention group
Intervention type: OTHER
Intervention: CTC surveillance
Description: In vivo CTC surveillance of 6-9 mm polyp
Study NCT04494724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: Infusion
Study NCT04494724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study NCT01404637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4mg
Description: Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
Study NCT01404637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.2mg
Description: tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
Study NCT01869465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-treatment snack
Description: The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
Study NCT01869465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education arm
Description: In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
Study NCT00130091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 2 mcg clonidine added to local anesthetic
Study NCT00130091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clonidine
Description: 2 mcg clonidine added to local anesthetic
Study NCT04417309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
Study NCT01805544 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
Study NCT04417309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for 30 minutes.
Study NCT02630186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
Study NCT01484522 — intervention group
Intervention type: BIOLOGICAL
Intervention: FluMist
Description: Administered at the manufacture's recommended dose
Study NCT01484522 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fluvirin
Description: Vaccine administered at the manufacturer's recommended dose.
Study NCT01484522 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fluzone
Description: Vaccine administered at manufacturer's recommended dose
Study NCT03845504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.